Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy
Access this Article
Search this Article
Author(s)
Journal
-
- Cancer science
-
Cancer science 108(10), 1959-1966, 2017-10
John Wiley & Sons